Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036690 (sepsis)
 59,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Staphylococcus aureus (SA) is among the most important causes of skin infections. The incidence of Methicillin-resistant SA (MRSA) strains isolated from skin and skin structure infections was about 20-40%. In deep-seated pyoderma such as furuncle and furunculosis, MRSA was more frequently isolated than in other type of infectious diseases of the skin. But the incidence was gradually increasing. As to coagulase typing, type IV was most frequently isolated in MRSA. The damaged skin is easily colonized by high numbers of SA on its surface and within hair follicles. Through the indwelling catheters or decubitus SA on the skin could cause easily severe systemic MRSA infections such as sepsis or endocarditis of in-patients.
 ...
PMID:[Methicillin-resistant Staphylococcus aureus in dermatology]. 150 40

Cellular antigens extracted from the cells of four Staphylococcus aureus strains from different kinds of infections (sepsis, osteomyelitis, furunculosis) were analysed by the western blotting technique. Antibiotic sensitivity pattern of the strains was compared. One isolate was found to be MRSA strain. Sera samples from patients of whom strains were isolated and four sera from blood donors (as a control) were used in the investigation. IgG levels for purified staphylococcal antigens (lipase, alpha-toxin and teichoic acid) were estimated. Interaction between extracted bacterial antigens and serum antibodies of IgG class were analysed in homologous and heterologous systems. The most strong immunological reaction of the investigated sera with staphylococcal antigens was observed in the case of homologous system. Serum from sepsis patient was found to be the most reactive serum with all staphylococcal antigens mixtures.
 ...
PMID:[Humoral response to Staphylococcus aureus antigens evaluated by the western blotting method]. 178 33

Some indices of humoral and cellular immunity were studied in 98 patients with diabetes mellitus (DM), complicated with pyoseptic infection (phlegmon, abscess, gangrene of different sites, hematogenic osteomyelitis, furunculosis, sepsis). A course of hyperbaric oxygenation (HBO) was conducted. Multimodality antidiabetic therapy in combination with HBO resulted in the improved general status of almost all DM patients, stimulation of reparative processes and wound defect closure were faster; DM compensation was achieved and ketoacidosis stopped. Normalization of laboratory and clinical indices was accompanied by immunological tests. The use of HBO in multimodality therapy of patients with DM complicated with pyoseptic infection brings about a good therapeutic effect.
 ...
PMID:[Hyperbaric oxygenation in the combined treatment of patients with diabetes mellitus complicated by a suppurative-septic infection]. 239 27

Lipase production of 425 S. aureus strains isolated from patients with different clinical diagnoses and healthy carriers were measured by a specific method, using emulsified trioleoylglycerol substrate. Strains isolated from patients with septicemia showed significantly higher lipase activity than osteomyelitis strains (p = 0.011), impetigo strains (p = 0.002) and strains isolated from healthy relatives of patients with recurrent furunculosis (p = 0.019). Recurrent furunculosis and pyomyositis strains had significantly higher (p = 0.002 and 0.032, respectively) lipase activity than septicemia strains. S. aureus strains isolated from patients with a significant antibody response in an antilipase ELISA did not show a higher lipase activity in culture supernatants than strains from patients without a significant antibody response. The lipase activity was significantly higher in strains isolated from deep or subcutaneous infections, i.e., septicemia, pyomyositis, osteomyelitis, aerobic and anaerobic furunculosis, than in strains from superficial infections, i.e. impetigo, or from nasal mucosa.
 ...
PMID:Lipolytic activity of Staphylococcus aureus strains from disseminated and localized infections. 359 10

Studies were carried out on the penetration of cefuzonam (L-105, CZON), a new synthetic cephalosporin antibiotic, into cerebrospinal fluid, and on the clinical efficacy against bacterial infections. The results are summarized as follows: Concentrations of CZON in cerebrospinal fluid at 1 hour after intravenous administration of 100 mg/kg in cases of furunculosis of the external canal, encephalitis and mumps meningitis were 0.56 micrograms/ml, 1.44 micrograms/ml and 0.33 micrograms/ml, respectively. Concentrations of CZON in cerebrospinal fluid at 1 hour after intravenous administration of 100 mg/kg in 3 cases of purulent meningitis were 2.80-6.40 micrograms/ml at the acute stage and 0.56-1.45 micrograms/ml even at the recovering stage. Sensitivities of clinically isolated strains to CZON were determined and expressed as MIC. MICs of CZON on Haemophilus influenzae, Escherichia coli, Proteus mirabilis and Klebsiella pneumoniae were similar to MIC's of cefmenoxime (CMX), and lower than those of cefoperazone (CPZ), cefmetazole (CMZ), cefatiam (CTM) and Cefazolin (CEZ). The MIC of CZON on Staphylococcus aureus was similar to those of CEZ, CMZ and CTM, and lower than those of CMX and CPZ. Clinical responses of CZON were good in 2 cases of purulent meningitis, good in 2 cases of pyothorax, excellent in 1 case of septicemia, excellent in 3 cases of urinary tract infections, excellent in 7 cases and good in 3 cases out of 10 cases of pneumonia. Clinical responses of other diseases were excellent in 4 cases of bronchitis, good in 1 case of furunculosis of the external canal, excellent in 1 case of tonsillitis. No side effects nor abnormal laboratory findings were observed except 2 cases of mild diarrhea out of 24 cases.
 ...
PMID:[Clinical evaluation of cefuzonam in pediatrics and a study on the penetration into cerebrospinal fluid]. 361 85

Purified Staphylococcus aureus lipase was used as antigen in an enzyme-linked immunosorbent assay (ELISA) that detected IgG antibodies in 169 patients with infections due to S. aureus, in 122 patients with infections not due to S. aureus, and in 167 healthy controls. Eighty-eight percent (21 of 24) of the patients with endocarditis due to S. aureus showed a positive level of antibody to lipase or a significant change in antibody titer during the first month, as did 89% (17 of 19) and 28% (5 of 18) of the patients with complicated and uncomplicated septicemia due to S. aureus, respectively. The specificity for S. aureus infections was high; only one patient in the non-S. aureus endocarditis and septicemia groups showed a significant rise in antibody titer, and this rise did not reach a positive antibody level. Patients with recurrent furunculosis or chronic osteomyelitis due to S. aureus responded in only 15% and 23% of cases, respectively. We suggest that the antibody-to-lipase ELISA could be used as a valuable complement to other serological assays in diagnosing serious S. aureus infections because of its high sensitivity and specificity.
 ...
PMID:A new serological assay for Staphylococcus aureus infections: detection of IgG antibodies to S. aureus lipase with an enzyme-linked immunosorbent assay. 403 44

Fundamental and clinical studies of ceftizoxime, a new cephalosporin antibiotic, in children led to the following results. 1. Ceftizoxime compared favorably with cefazolin (CEZ) and cefmetazole (CMZ) for in vitro activity against clinically isolated strains of Staphylococcus aureus (31 strains), Escherichia coli (29), Klebsiella pneumoniae (30) and Pseudomonas aeruginosa (16). While somewhat less active against S. aureus than CEZ and CMZ, ceftizoxime was far more active than these 2 cephalosporin antibiotics against the test strains of E. coli and K. pneumoniae, which included strains resistant to the 2 drugs. Ceftizoxime was not particularly active against Ps. aeruginosa, but this seeming disadvantage was offset by the absolute ineffectiveness of the 2 reference drugs on this obstinate organism. 2. The time course of mean serum ceftizoxime levels in 3 pediatric patients of 5--10 years old given a single intravenous dose of 20 mg/kg was as follows: 45.4 micrograms/ml at 15 minutes, 40.4 micrograms/ml at 30 minutes, 22.1 micrograms/ml at 1 hour, 10.4 micrograms/ml at 2 hours, 2.9 micrograms/ml at 4 hours and 0.9 microgram/ml at 6 hours. The mean serum half life was 1.12 hours. The mean urinary levels of ceftizoxime at serial 2-hour collection intervals were as follows: 2,477 micrograms/ml for 1--2 hours, 1,235 micrograms/ml for 2--4 hours and 462 micrograms/ml for 4--6 hours. The mean urinary recovery up to 6 hours was 61.0%. 3. The clinical response of 28 children with infection to ceftizoxime treatment was 'excellent' in 22 children, 'good' in 4, and 'poor' in 2. These children comprised 11 with acute pneumonia, 3 with acute bronchitis, 4 with acute pyelonephritis, 2 each with acute purulent arthritis and acute enterocolitis, and 1 each with acute purulent tonsillitis, acute purulent lymphadenitis, furunculosis, subcutaneous abscess, subdural abscess and sepsis. The overall rate of effectiveness was 92.9%. Successfully eradicated strains in the bacteriological sense consisted of 4 strains each of H. influenzae and E. coli, 1 strain each of P. morganii, S. pneumoniae and S. pyogenes, 1 of the 2 strains of S. enteritidis, and 1 of the 3 strains of S. aureus. The overall rate of bacteriological effectiveness was 81.3%. No clinical side effects were observed. Changes in laboratory test findings included slightly and transiently elevated GOT and GPT in 1 child and GOT alone in another child.
 ...
PMID:[Fundamental and clinical studies on ceftizoxime in pediatric field (author's transl)]. 627 13

One hundred and nineteen patients with S. aureus infections and 22 patients with non-S. aureus septicemia were investigated for anti-alpha hemolysin antibodies using a radioimmunoassay (RIA). As compared to 16- healthy controls, patients with S. aureus endocarditis, septicemia, chronic osteomyelitis and recurrent furunculosis showed significantly higher antibody levels, while the non-S. aureus septicemia group showed normal levels. Corresponding results were obtained using the conventional anti-staphylolysin (ASTA) test. Only patients with recurrent furunculosis had significantly elevated anti-beta hemolysin antibody levels assessed by RIA, in comparison with healthy controls. The highest antibody levels were found in furunculosis patients infected with S. aureus strains which were high producers of beta hemolysin. The results indicate that furunculosis patients do not have a defective serological response against S. aureus beta hemolysin.
 ...
PMID:Antibody response to alpha- and betahemolysin from Staphylococcus aureus in patients with staphylococcal infections and in normals. 665 35

A solid-phase radioimmunoassay (SPRIA) for determination of antibodies against S. aureus peptidoglycan was used for serological diagnosis of staphylococcal infections. Elevated IgG antibody levels were found in 21/21 patients with S. aureus endocarditis and in 10/24 patients with S. aureus septicemia. Two patients with streptococcal and one patient with pneumococcal septicemia showed elevated antibody levels as well, probably due to cross reactions between peptidoglycans of different bacterial species. In cases of chronic osteomyelitis caused by S. aureus, 12/33 patients showed elevated antibody levels while all patients with recurrent furunculosis had normal antibody levels. Anti-peptidoglycan antibodies were also found in all healthy controls (n = 160) but at lower levels. This might explain the rapid booster response of IgG antibodies found in 73 per cent of patients with S. aureus endocarditis already within 10 days after the first symptoms. The best clinical value of the assay seems to be in separating S. aureus endocarditis from uncomplicated septicemia.
 ...
PMID:Solid-phase radioimmunoassay of immunoglobulin G antibodies to Staphylococcus aureus peptidoglycan in patients with staphylococcal infections. 667

One hundred and thirteen patients with S. aureus infections, eight patients with non-S. aureus septicemia and 167 normal controls were investigated by solid-phase radioimmunoassay for staphylococcal antibodies. All serum samples tested had measurable antibodies, including the normal controls. The test could differentiate the patients group with S. aureus endocarditis from patients with other S. aureus septicemia, as well as from normal controls, as the endocarditis group had significantly higher antibody levels. Patients with non-bacteremic S. aureus infections, such as osteomyelitis and recurrent furunculosis, showed a wide range of antibody levels, 1/3 and 1/4 of the patients, respectively, showing high levels comparable to the endocarditis patients. Among normal controls, high antibody levels were found in 13 per cent.
 ...
PMID:Detection of Staphylococcus aureus antibodies in patients with S. aureus infections and in normal persons, using solid phase radioimmunoassay. 712 7


1 2 3 Next >>